BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31481237)

  • 21. Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin.
    Spudich JA; Aksel T; Bartholomew SR; Nag S; Kawana M; Yu EC; Sarkar SS; Sung J; Sommese RF; Sutton S; Cho C; Adhikari AS; Taylor R; Liu C; Trivedi D; Ruppel KM
    J Exp Biol; 2016 Jan; 219(Pt 2):161-7. PubMed ID: 26792326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position.
    Mun JY; Kensler RW; Harris SP; Craig R
    J Mol Cell Cardiol; 2016 Feb; 91():141-7. PubMed ID: 26718724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional consequences of a mutation in an expressed human alpha-cardiac actin at a site implicated in familial hypertrophic cardiomyopathy.
    Bookwalter CS; Trybus KM
    J Biol Chem; 2006 Jun; 281(24):16777-84. PubMed ID: 16611632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of actin-cardiac myosin subfragment 1 MgATPase rate by Ca2+ shows cooperativity intrinsic to the thin filament.
    Tobacman LS
    Biochemistry; 1987 Jan; 26(2):492-7. PubMed ID: 2950924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.
    Roopnarine O; Leinwand LA
    Biophys J; 1998 Dec; 75(6):3023-30. PubMed ID: 9826622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction.
    Sweeney HL; Straceski AJ; Leinwand LA; Tikunov BA; Faust L
    J Biol Chem; 1994 Jan; 269(3):1603-5. PubMed ID: 8294404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.
    Lowey S; Bretton V; Joel PB; Trybus KM; Gulick J; Robbins J; Kalganov A; Cornachione AS; Rassier DE
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):11238-11243. PubMed ID: 30322937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C0 and C1 N-terminal Ig domains of myosin binding protein C exert different effects on thin filament activation.
    Harris SP; Belknap B; Van Sciver RE; White HD; Galkin VE
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1558-63. PubMed ID: 26831109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis.
    Karibe A; Tobacman LS; Strand J; Butters C; Back N; Bachinski LL; Arai AE; Ortiz A; Roberts R; Homsher E; Fananapazir L
    Circulation; 2001 Jan; 103(1):65-71. PubMed ID: 11136687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertrophic cardiomyopathy-linked variants of cardiac myosin-binding protein C3 display altered molecular properties and actin interaction.
    Da'as SI; Fakhro K; Thanassoulas A; Krishnamoorthy N; Saleh A; Calver BL; Safieh-Garabedian B; Toft E; Nounesis G; Lai FA; Nomikos M
    Biochem J; 2018 Dec; 475(24):3933-3948. PubMed ID: 30446606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Delta 14 mutation of human cardiac troponin T enhances ATPase activity and alters the cooperative binding of S1-ADP to regulated actin.
    Gafurov B; Fredricksen S; Cai A; Brenner B; Chase PB; Chalovich JM
    Biochemistry; 2004 Dec; 43(48):15276-85. PubMed ID: 15568820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphorylation of human cardiac troponin I G203S and K206Q linked to familial hypertrophic cardiomyopathy affects actomyosin interaction in different ways.
    Deng Y; Schmidtmann A; Kruse S; Filatov V; Heilmeyer LM; Jaquet K; Thieleczek R
    J Mol Cell Cardiol; 2003 Nov; 35(11):1365-74. PubMed ID: 14596793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy.
    Cuda G; Fananapazir L; Zhu WS; Sellers JR; Epstein ND
    J Clin Invest; 1993 Jun; 91(6):2861-5. PubMed ID: 8514894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Troponin C Mutations Partially Stabilize the Active State of Regulated Actin and Fully Stabilize the Active State When Paired with Δ14 TnT.
    Baxley T; Johnson D; Pinto JR; Chalovich JM
    Biochemistry; 2017 Jun; 56(23):2928-2937. PubMed ID: 28530094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy.
    Cuda G; Fananapazir L; Epstein ND; Sellers JR
    J Muscle Res Cell Motil; 1997 Jun; 18(3):275-83. PubMed ID: 9172070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
    O'Leary TS; Snyder J; Sadayappan S; Day SM; Previs MJ
    J Mol Cell Cardiol; 2019 Feb; 127():165-173. PubMed ID: 30550750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level.
    Palmiter KA; Tyska MJ; Haeberle JR; Alpert NR; Fananapazir L; Warshaw DM
    J Muscle Res Cell Motil; 2000; 21(7):609-20. PubMed ID: 11227787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
    Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
    Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The L-type Ca(2+) channel facilitates abnormal metabolic activity in the cTnI-G203S mouse model of hypertrophic cardiomyopathy.
    Viola H; Johnstone V; Cserne Szappanos H; Richman T; Tsoutsman T; Filipovska A; Semsarian C; Hool L
    J Physiol; 2016 Jul; 594(14):4051-70. PubMed ID: 27062056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of apical hypertrophic cardiomyopathy with age in a transgenic mouse model carrying the cardiac actin E99K mutation.
    Wang L; Bai F; Zhang Q; Song W; Messer A; Kawai M
    J Muscle Res Cell Motil; 2017 Dec; 38(5-6):421-435. PubMed ID: 29582353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.